Related Experiment Video

Updated: Nov 14, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.4K

BiTE-ing into Prostate Cancer with Bispecific T-cell Engagers

Nikhil V Kamat1,2, Evan Y Yu1,3, John K Lee4,2,3

  • 1Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 12, 2021
PubMed

Insights

A novel bispecific T-cell engager, AMG 160, shows preclinical promise by targeting prostate-specific membrane antigen (PSMA) to activate T-cells against prostate cancer.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Prostate-specific membrane antigen (PSMA) is a key target in prostate cancer therapy.
  • Immuno-oncology approaches are emerging as vital therapeutic strategies.

Purpose of the Study:

  • To evaluate the preclinical efficacy of AMG 160, a novel half-life extended bispecific T-cell engager.
  • To assess the ability of AMG 160 to induce T-cell-mediated cytolytic activity against prostate cancer cells.

Main Methods:

  • Preclinical studies were conducted to assess the efficacy of AMG 160.
  • AMG 160 was designed to bind both prostate-specific membrane antigen (PSMA) and CD3.

Main Results:

  • AMG 160 demonstrated preclinical efficacy in targeting prostate cancer.
  • The bispecific T-cell engager induced T-cell-driven cytolytic activity.

Conclusions:

  • Half-life extended bispecific T-cell engagers targeting PSMA represent a promising therapeutic avenue.
  • AMG 160 shows potential for immune oncology in prostate cancer treatment.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.7K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
826
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
617
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.2K